Top

Published in:

Open Access 01-12-2018 | Review article

Protective effects of PACAP in ischemia

Authors: Dora Reglodi, Alexandra Vaczy, Eloísa Rubio-Beltran, Antoinette MaassenVanDenBrink

Published in: The Journal of Headache and Pain | Issue 1/2018

Abstract

Pituitary adenylate cyclase activating polypeptide (PACAP) is an ubiquitous peptide involved, among others, in neurodevelopment, neuromodulation, neuroprotection, neurogenic inflammation and nociception. Presence of PACAP and its specific receptor, PAC1, in the trigeminocervical complex, changes of PACAP levels in migraine patients and the migraine-inducing effect of PACAP injection strongly support the involvement of PACAP/PAC1 receptor in migraine pathogenesis. While antagonizing PAC1 receptor is a promising therapeutic target in migraine, the diverse array of PACAP’s functions, including protection in ischemic events, requires that the cost-benefit of such an intervention is well investigated by taking all the beneficial effects of PACAP into account. In the present review we summarize the protective effects of PACAP in ischemia, especially in neuronal ischemic injuries, and discuss possible points to consider when developing strategies in migraine therapy interfering with the PACAP/PAC1 receptor system.

Miyata A, Arimura A, Dahl RR, Minamino N, Uehara A, Jiang L, Culler MD, Coy DH (1989) Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 164(1):567–574PubMedCrossRef

Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, Vaudry H (2000) Pituitary adenylate ayclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev 52(2):269–324PubMed

Arimura A (1992) Receptors for pituitary adenylate cyclase-activating polypeptide comparison with vasoactive intestinal peptide receptors. Trends Endocrinol Metab 3(8):288–294PubMedCrossRef

Laburthe M, Couvineau A, Marie JC (2002) VPAC receptors for VIP and PACAP. Receptors Channels 8(3–4):137–153PubMedCrossRef

Masuo Y, Ohtaki T, Masuda Y, Nagai Y, Suno M, Tsuda M, Fujino M (1991) Autoradiographic distribution of pituitary adenylate cyclase activating polypeptide (PACAP) binding sites in the rat brain. Neurosci Lett 126(2):103–106PubMedCrossRef

Masuo Y, Suzuki N, Matsumoto H, Tokito F, Matsumoto Y, Tsuda M, Fujino M (1993) Regional distribution of pituitary adenylate cyclase activating polypeptide (PACAP) in the rat central nervous system as determined by sandwich-enzyme immunoassay. Brain Res 602(1):57–63PubMedCrossRef

Uddman R, Tajti J, Hou M, Sundler F, Edvinsson L (2002) Neuropeptide expression in the human trigeminal nucleus caudalis and in the cervical spinal cord C1 and C2. Cephalalgia 22(2):112–116PubMedCrossRef

Narita M, Dun SL, Dun NJ, Tseng LF (1996) Hyperalgesia induced by pituitary adenylate cyclase-activating polypeptide in the mouse spinal cord. Eur J Pharmacol 311(2–3):121–126PubMedCrossRef

Tajti J, Uddman R, Edvinsson L (2001) Neuropeptide localization in the ‘migraine generator’ region of the human brainstem. Cephalalgia 21(2):96–101PubMedCrossRef

10.

Vigh S, Arimura A, Koves K, Somogyvari-Vigh A, Sitton J, Fermin CD (1991) Immunohistochemical localization of the neuropeptide, pituitary adenylate cyclase activating polypeptide (PACAP), in human and primate hypothalamus. Peptides 12(2):313–318PubMedCrossRef

11.

Gottschall PE, Tatsuno I, Miyata A, Arimura A (1990) Characterization and distribution of binding sites for the hypothalamic peptide, pituitary adenylate cyclase-activating polypeptide. Endocrinology 127(1):272–277PubMedCrossRef

12.

Koves K, Arimura A, Somogyvari-Vigh A, Vigh S, Miller JIM (1990) Immunohistochemical demonstration of a novel hypothalamic peptide, pituitary adenylate cyclase-activating polypeptide, in the ovine hypothalamus. Endocrinology 127(1):264–271PubMedCrossRef

13.

Gourlet P, Woussen-Colle MC, Robberecht P, Neef P, Cauvin A, Vandermeers-Piret MC, Vandermeers A, Christophe J (1991) Structural requirements for the binding of the pituitary adenylate-cyclase-activating peptide to receptors and adenylate-cyclase activation in pancreatic and neuronal membranes. Eur J Biochem 195(2):535–541PubMedCrossRef

14.

Tatsuno I, Gottschall PE, Koves K, Arimura A (1990) Demonstration of specific binding sites for pituitary adenylate cyclase activating polypeptide (PACAP) in rat astrocytes. Biochem Biophys Res Commun 168(3):1027–1033PubMedCrossRef

15.

Schytz HW, Birk S, Wienecke T, Kruuse C, Olesen J, Ashina M (2009) PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain 132(Pt1):16–25PubMedCrossRef

16.

Robert C, Bourgeais L, Arreto CD, Condes-Lara M, Noseda R, Jay T, Villanueva L (2013) Paraventricular hypothalamic regulation of trigeminovascular mechanisms involved in headaches. J Neurosci 33(20):8827–8840PubMedCrossRef

17.

Tuka B, Helyes Z, Markovics A, Bagoly T, Szolcsanyi J, Szabo N, Toth E, Kincses ZT, Vecsei L, Tajti J (2013) Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients. Cephalalgia 33(13):1085–1095PubMedCrossRef

18.

Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J (2002) CGRP may play a causative role in migraine. Cephalalgia 22(1):54–61PubMedCrossRef

19.

Chan KY, Baun M, de Vries R, van den Bogaerdt AJ, Dirven CM, Danser AH, Jansen-Olesen I, Olesen J, Villalon CM, Maassen Van DenBrink A, Gupta S (2011) Pharmacological characterization of VIP and PACAP receptors in the human meningeal and coronary artery. Cephalalgia 31(2):181–189PubMedCrossRef

20.

Rahmann A, Wienecke T, Hansen JM, Fahrenkrug J, Olesen J, Ashina M (2008) Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine. Cephalalgia 28(3):226–236PubMedCrossRef

21.

Lam HC, Takahashi K, Ghatei MA, Kanse SM, Polak JM, Bloom SR (1990) Binding sites of a novel neuropeptide pituitary-adenylate-cyclase-activating polypeptide in the rat brain and lung. Eur J Biochem 193(3):725–729PubMedCrossRef

22.

Uddman R, Luts A, Arimura A, Sundler F (1991) Pituitary adenylate cyclase-activating peptide (PACAP), a new vasoactive intestinal peptide (VIP)-like peptide in the respiratory tract. Cell Tissue Res 265(1):197–201PubMedCrossRef

23.

Fahrenkrug J, Hannibal J (2011) Localisation of the neuropeptide PACAP and its receptors in the rat parathyroid and thyroid glands. Gen Comp Endocrinol 171(1):105–113PubMedCrossRef

24.

Lauffer JM, Modlin IM, Tang LH (1999) Biological relevance of pituitary adenylate cyclase-activating polypeptide (PACAP) in the gastrointestinal tract. Regul Pept 84(1–3):1–12CrossRef

25.

Lenti L, Domoki F, Kis D, Hegyi O, Toth GK, Busija DW, Bari F (2007) Pituitary adenylate cyclase-activating polypeptide induces pial arteriolar vasodilation through cyclooxygenase-dependent and independent mechanisms in newborn pigs. Brain Res 1165:81–88PubMedCrossRef

26.

Atlasz T, Babai N, Kiss P, Reglodi D, Tamas A, Szabadfi K, Toth G, Hegyi O, Lubics A, Gabriel R (2007) Pituitary adenylate cyclase activating polypeptide is protective in bilateral carotid occlusion-induced retinal lesion in rats. Gen Comp Endocrinol 153:108–114PubMedCrossRef

27.

Reglodi D, Tamas A, Somogyvari-Vigh A, Szanto Z, Kertes E, Lenard L, Arimura A, Lengvari I (2002) Effects of pretreatment with PACAP on the infarct size and functional outcome in rat permanent focal cerebral ischemia. Peptides 23(12):2227–2234PubMedCrossRef

28.

Reglodi D, Tamas A, Lubics A, Szalontay L, Lengvari I (2004) Morphological and functional effects of PACAP in 6-hydroxydopamine-induced lesion of the substantia nigra in rats. Regul Pept 123(1–3):85–94PubMedCrossRef

29.

Babai N, Atlasz T, Tamas A, Reglodi D, Toth G, Kiss P, Gabriel R (2005) Degree of damage compensation by various PACAP treatments in monosodium glutamate-induced retinal degeneration. Neurotox Res 8(3–4):227–233PubMedCrossRef

30.

Reglodi D, Lubics A, Kiss P, Lengvari I, Gaszner B, Toth G, Hegyi O, Tamas A (2006) Effect of PACAP in 6-OHDA-induced injury of the substantia nigra in intact young and ovariectomized female rats. Neuropeptides 40(4):265–274PubMedCrossRef

31.

Racz B, Gallyas F, Kiss P, Toth G, Hegyi O, Gasz B, Borsiczky B, Ferencz A, Roth E, Tamas A, Lengvari I, Lubics A, Reglodi D (2006) The neuroprotective effects of PACAP in monosodium glutamate-induced retinal lesion involve inhibition of proapoptotic signaling pathways. Regul Pept 137(1–2):20–26PubMedCrossRef

32.

Tamas A, Lubics A, Lengvari I, Reglodi D (2006) Protective effects of PACAP in excitotoxic striatal lesion. Ann N Y Acad Sci 1070:570–574PubMedCrossRef

33.

Somogyvari-Vigh A, Reglodi D (2004) Pituitary adenylate cyclase activating polypeptide: a potential neuroprotective peptide. Curr Pharm Des 10(23):2861–2889PubMedCrossRef

34.

Atlasz T, Vaczy A, Werling D, Kiss P, Tamas A, Kovacs K, Fabian E, Kvarik T, Mammel B, Danyadi B, Lokos E, Reglodi D (2016) Neuroprotective effects of PACAP in the retina. In: Reglodi D, Tamas A (eds) Pituitary adenylate cyclase activating polypeptide-PACAP, vol 11. Springer Nature, New York, pp 501–527CrossRef

35.

Ohtaki H, Nakamachi T, Dohi K, Shioda S (2008) Role of PACAP in ischemic neural death. J Mol Neurosci 36:16–25PubMedCrossRef

36.

Uchida D, Arimura A, Somogyvári-Vigh A, Shioda S, Banks WA (1996) Prevention of ischemia-induced death of hippocampal neurons by pituitary adenylate cyclase activating polypeptide. Brain Res 736(1–2):280–286PubMedCrossRef

37.

Dohi K, Mizushima H, Nakajo S, Ohtaki H, Matsunaga S, Aruga T, Shioda S (2002) Pituitary adenylate cyclase-activating polypeptide (PACAP) prevents hippocampal neurons from apoptosis by inhibiting JNK/SAPK and p38 signal transduction pathways. Regul Pept 109(1–3):83–88PubMedCrossRef

38.

Banks WA, Uchida D, Arimura A, Somogyvari-Vigh A, Shioda S (1996) Transport of pituitary adenylate cyclase-activating polypeptide across the blood-brain barrier and the prevention of ischemia-induced death of hippocampal neurons. Ann N Y Acad Sci 805:270–277PubMedCrossRef

39.

Shioda S, Ozawa H, Dohi K, Mizushima H, Matsumoto K, Nakajo S, Takaki A, Zhou CJ, Nakai Y, Arimura A (1998) PACAP protects hippocampal neurons against apoptosis: involvement of JNK/SAPK signaling pathway. Ann N Y Acad Sci 865:111–117PubMedCrossRef

40.

Ohtaki H, Nakamachi T, Dohi K, Aizawa Y, Takaki A, Hodoyama K, Yofu S, Hashimoto H, Shintani N, Baba A, Kopf M, Iwakura Y, Matsuda K, Arimura A, Shioda S (2006) Pituitary adenylate cyclase-activating polypeptide (PACAP) decreases ischemic neuronal cell death in association with IL-6. Proc Natl Acad Sci 103(19):7488–7493PubMedPubMedCentralCrossRef

41.

Lazarovici P, Cohen G, Arien-Zakay H, Chen J, Zhang C, Chopp M, Jiang H (2012) Multimodal neuroprotection induced by PACAP38 in oxygen–glucose deprivation and middle cerebral artery occlusion stroke models. J Mol Neurosci 48(3):526–540PubMedPubMedCentralCrossRef

42.

Tamas A, Reglodi D, Szanto Z, Borsiczky B, Nemeth J, Lengvari I (2002) Comparative neuroprotective effects of preischemic PACAP and VIP administration in permanent occlusion of the middle cerebral artery in rats. Neuro Endocrinol Lett 23(3):249–254PubMed

43.

Reglodi D, Somogyvari-Vigh A, Vigh S, Kozicz T, Arimura A (2000) Delayed systemic administration of PACAP38 is neuroprotective in transient middle cerebral artery occlusion in the rat. Stroke 31(6):1411–1417PubMedCrossRef

44.

Reglodi D, Somogyvari-Vigh A, Vigh S, Maderdrut JL, Arimura A (2000) Neuroprotective effects of PACAP38 in a rat model of transient focal ischemia under various experimental conditions. Ann N Y Acad Sci 921:119–128PubMedCrossRef

45.

Reglodi D, Fabian Z, Tamas A, Lubics A, Szeberenyi J, Alexy T, Toth K, Marton Z, Borsiczky B, Roth E, Szalontay L, Lengvari I (2004) Effects of PACAP on in vitro and in vivo neuronal cell death, platelet aggregation, and production of reactive oxygen radicals. Regul Pept 123(1–3):51–59PubMedCrossRef

46.

Dejda A, Seaborn T, Bourgault S, Touzani O, Fournier A, Vaudry H, Vaudry D (2011) PACAP and a novel stable analog protect rat brain from ischemia: insight into the mechanisms of action. Peptides 32(6):1207–1216PubMedCrossRef

47.

Brifault C, Gras M, Liot D, May V, Vaudry D, Wurtz O (2015) Delayed pituitary adenylate cyclase-activating polypeptide delivery after brain stroke improves functional recovery by inducing m2 microglia/macrophage polarization. Stroke 46(2):520–528PubMedCrossRef

48.

Stetler RA, Gao Y, Zukin RS, Vosler PS, Zhang L, Zhang F, Cao G, Bennett MV, Chen J (2010) Apurinic/apyrimidinic endonuclease APE1 is required for PACAP-induced neuroprotection against global cerebral ischemia. Proc Natl Acad Sci U S A 107(7):3204–3209PubMedPubMedCentralCrossRef

49.

Hori M, Nakamachi T, Shibato J, Rakwal R, Shioda S, Numazawa S (2015) Unraveling the specific ischemic core and penumbra transcriptome in the permanent middle cerebral artery occlusion mouse model brain treated with the neuropeptide PACAP38. Microarrays (Basel) 4(1):2–24CrossRef

50.

Hori M, Shibato J, Nakamachi T, Rakwal R, Ogawa T, Shioda S, Numazawa S (2015) Two-color dye-swap DNA microarray approach toward confident gene expression profiling in PMCAO mouse model for ischemia-related and PACAP38-influenced genes. Genom Data 3:148–154PubMedPubMedCentralCrossRef

51.

Hori M, Nakamachi T, Shibato J, Rakwal R, Tsuchida M, Shioda S, Numazawa S (2014) PACAP38 differentially effects genes and CRMP2 protein expression in ischemic core and penumbra regions of permanent middle cerebral artery occlusion model mice brain. Int J Mol Sci 15(9):17014–17034PubMedPubMedCentralCrossRef

52.

Hori M, Nakamachi T, Rakwal R, Shibato J, Ogawa T, Aiuchi T, Tsuruyama T, Tamaki K, Shioda S (2012) Transcriptomics and proteomics analyses of the PACAP38 influenced ischemic brain in permanent middle cerebral artery occlusion model mice. J Neuroinflammation 9:256PubMedPubMedCentralCrossRef

53.

Maugeri G, D'Amico AG, Saccone S, Federico C, Cavallaro S, D'Agata V (2017) PACAP and VIP inhibit HIF-1α-mediated VEGF expression in a model of diabetic macular edema. J Cell Physiol 232(5):1209–1215PubMedCrossRef

54.

D'Amico AG, Maugeri G, Reitano R, Bucolo C, Saccone S, Drago F, D'Agata V (2015) PACAP modulates expression of hypoxia-inducible factors in streptozotocin-induced diabetic rat retina. J Mol Neurosci 57(4):501–509PubMedCrossRef

55.

Lin CH, Chiu L, Lee HT, Chiang CW, Liu SP, Hsu YH, Lin SZ, Hsu CY, Hsieh CH, Shyu WC (2015) PACAP38/PAC1 signaling induces bone marrow-derived cells homing to ischemic brain. Stem Cells 33(4):1153–1172PubMedPubMedCentralCrossRef

56.

Doeppner TR, Kaltwasser B, Schlechter J, Jaschke J, Kilic E, Bahr M, Hermann DM, Weise J (2015) Cellular prion protein promotes post-ischemic neuronal survival, angioneurogenesis and enhances neural progenitor cell homing via proteasome inhibition. Cell Death Dis 6:e2024PubMedPubMedCentralCrossRef

57.

Lamine A, Letourneau M, Doan ND, Maucotel J, Couvineau A, Vaudry H, Chatenet D, Vaudry D, Fournier A (2016) Characterizations of a synthetic pituitary adenylate cyclase-activating polypeptide analog displaying potent neuroprotective activity and reduced in vivo cardiovascular side effects in a Parkinson's disease model. Neuropharmacology 108:440–450PubMedCrossRef

58.

Somogyvari-Vigh A, Pan W, Reglodi D, Kastin AJ, Arimura A (2000) Effect of middle cerebral artery occlusion on the passage of pituitary adenylate cyclase activating polypeptide across the blood-brain barrier in the rat. Regul Pept 91(1–3):89–95PubMedCrossRef

59.

Dogrukol-Ak D, Kumar VB, Ryerse JS, Farr SA, Verma S, Nonaka N, Nakamachi T, Ohtaki H, Niehoff ML, Edwards JC, Shioda S, Morley JE, Banks WA (2009) Isolation of peptide transport system-6 from brain endothelial cells: therapeutic effects with antisense inhibition in Alzheimer and stroke models. J Cereb Blood Flow Metab 29(2):411–422PubMedCrossRef

60.

Ohtaki H, Dohi K, Yofu S, Nakamachi T, Kudo Y, Endo S, Aruga T, Goto N, Watanabe J, Kikuyama S, Shioda S (2004) Effect of pituitary adenylate cyclase-activating polypeptide 38 (PACAP38) on tissue oxygen content--treatment in central nervous system of mice. Regul Pept 123(1–3):61–67PubMedCrossRef

61.

Ivic I, Fulop BD, Juhasz T, Reglodi D, Toth G, Hashimoto H, Tamas A, Koller A (2017) Backup Mechanisms Maintain PACAP/VIP-Induced Arterial Relaxations in Pituitary Adenylate Cyclase-Activating Polypeptide-Deficient Mice. J Vasc Res 54:180–192PubMedCrossRef

62.

Amin FM, Asghar MS, Guo S, Hougaard A, Hansen AE, Schytz HW, van der Geest RJ, de Koning PJ, Larsson HB, Olesen J, Ashina M (2012) Headache and prolonged dilatation of the middle meningeal artery by PACAP38 in healthy volunteers. Cephalalgia 32:140–149PubMedCrossRef

63.

Edvinsson L (2016) Pituitary adenylate cyclase activating polypeptide (PACAP) in migraine pathophysiology. In: Pituitary adenylate cyclase activating polypeptide-PACAP, volume 11. Springer Nature, New York, pp 583–606

64.

Shin CM, Chung YH, Kim MJ, Cha CI (2001) Spatial and temporal distribution of pituitary adenylate cyclase activating polypeptide in gerbil global cerebral ischemia. Neurosci Lett 309(1):53–56PubMedCrossRef

65.

Gillardon F, Hata R, Hossmann KA (1998) Delayed up-regulation of Zac1 and PACAP type I receptor after transient focal cerebral ischemia in mice. Brain Res Mol Brain Res 61(1–2):207–210PubMedCrossRef

66.

Ciani E, Hoffmann A, Schmidt P, Journot L, Spengler D (1999) Induction of the PAC1-R (PACAP-type I receptor) gene by p53 and Zac. Brain Res Mol Brain Res 69(2):290–294PubMedCrossRef

67.

Stumm R, Kolodziej A, Prinz V, Endres M, Wu DF, Hollt V (2007) Pituitary adenylate cyclase-activating polypeptide is up-regulated in cortical pyramidal cells after focal ischemia and protects neurons from mild hypoxic/ischemic damage. J Neurochem 103(4):1666–1681PubMedCrossRef

68.

Riek-Burchardt M, Kolodziej A, Henrich-Noack P, Reymann KG, Hollt V, Stumm R (2010) Differential regulation of CXCL12 and PACAP mRNA expression after focal and global ischemia. Neuropharmacology 58(1):199–207PubMedCrossRef

69.

Nakamachi T, Farkas J, Kagami N, Wada Y, Hori M, Tsuchikawa D, Tsuchida M, Yoshikawa A, Imai N, Hosono T, Atrata S, Shioda S (2013) Expression and distribution of pituitary adenylate cyclase-activating polypeptide receptor in reactive astrocytes induced by global brain ischemia in mice. Acta Neurochir Suppl 118:55–59PubMed

70.

Nakamachi T, Tsuchida M, Kagami N, Yofu S, Wada Y, Hori M, Tsuchikawa D, Yoshikawa A, Imai N, Nakamura K, Arata S, Shioda S (2012) IL-6 and PACAP receptor expression and localization after global brain ischemia in mice. J Mol Neurosci 48(3):518–525PubMedCrossRef

71.

Nakamachi T, Ohtaki H, Yofu S, Dohi K, Watanabe J, Mori H, Sato A, Hashimoto H, Shintani N, Baba A, Shioda S (2010) Endogenous pituitary adenylate cyclase activating polypeptide is involved in suppression of edema in the ischemic brain. Acta Neurochir Suppl 106:43–46PubMedCrossRef

72.

Matsumoto M, Nakamachi T, Watanabe J, Sugiyama K, Ohtaki H, Murai N, Sasaki S, Xu Z, Hashimoto H, Seki T, Miyazaki A, Shioda S (2016) Pituitary adenylate cyclase-activating polypeptide (PACAP) is involved in adult mouse hippocampal neurogenesis after stroke. J Mol Neurosci 59(2):270–279PubMedCrossRef

73.

Ma BQ, Zhang M, Ba L (2015) Plasma pituitary adenylate cyclase-activating polypeptide concentrations and mortality after acute spontaneous basal ganglia hemorrhage. Clin Chim Acta 439:102–106PubMedCrossRef

74.

Jiang L, Wang WH, Dong XQ, Yu WH, Du Q, Yang DB, Wang H, Shen YF (2016) The change of plasma pituitary adenylate cyclase-activating polypeptide levels after aneurysmal subarachnoid hemorrhage. Acta Neurol Scand 134(2):131–139PubMedCrossRef

75.

Atlasz T, Szabadfi K, Kiss P, Racz B, Gallyas F, Tamas A, Gaal V, Marton Z, Gabriel R, Reglodi D (2010) Pituitary adenylate cyclase activating polypeptide in the retina: focus on the retinoprotective effects. Ann N Y Acad Sci 1200:128–139PubMedCrossRef

76.

Atlasz T, Szabadfi K, Kiss P, Tamas A, Toth G, Reglodi D, Gabriel R (2010) Evaluation of the protective effects of PACAP with cell-specific markers in ischemia-induced retinal degeneration. Brain Res Bull 81:497–504PubMedCrossRef

77.

Cervia D, Casini G (2013) The neuropeptide systems and their potential role in the treatment of mammalian retinal ischemia: a developing story. Curr Neuropharmacol 11:95–101PubMedPubMedCentral

78.

Shioda S, Takenoya F, Wada N, Hirabayashi T, Seki T, Nakamachi T (2016) Pleiotropic and retinoprotective functions of PACAP. Anat Sci Int 4:313–324CrossRef

79.

Nakamachi T, Matkovits A, Seki T, Shioda S (2012) Distribution and protective function of pituitary adenylate cyclase-activating polypeptide in the retina. Front Endocrinol (Lausanne) 3:145

80.

Szabadfi K, Mester L, Reglodi D, Kiss P, Babai N, Racz B, Kovacs K, Szabo A, Tamas A, Gabriel R, Atlasz T (2010) Novel neuroprotective strategies in ischemic retinal lesions. Int J Mol Sci 11:544–561PubMedPubMedCentralCrossRef

81.

Danyadi B, Szabadfi K, Reglodi D, Mihalik A, Danyadi T, Kovacs Zs BI, Tamas A, Kiss P, Toth G, Gabriel R (2014) PACAP application improves functional outcome of chronic retinal ischemic injury in rats – evidence from electroretinographic measurements. J Mol Neurosci 54:293–299PubMedCrossRef

82.

Szabadfi K, Atlasz T, Kiss P, Danyadi B, Tamas A, Helyes Zs HH, Shintani N, Baba A, Toth G, Gabriel R, Reglodi D (2012a) Mice deficient in pituitary adenylate cyclase activating polypeptide (PACAP) are more susceptible to retinal ischemic injury in vivo. Neurotox Res 21:41–48PubMedCrossRef

83.

Seki T, Itoh H, Nakamachi T, Endo K, Wada Y, Nakamura K, Shioda S (2011) Suppression of rat retinal ganglion cell death by PACAP following transient ischemia induced by high intraocular pressure. J Mol Neurosci 43:30–34PubMedCrossRef

84.

Werling D, Reglodi D, Kiss P, Toth G, Szabadfi K, Tamas A, Biro Z, Atlasz T (2014) Investigation of PACAP fragments and related peptides in chronic retinal hypoperfusion. J Ophthalmol 2014:563812PubMedPubMedCentralCrossRef

85.

Atlasz T, Szabadfi K, Reglodi D, Kiss P, Tamas A, Toth G, Molnar A, Szabo K, Gabriel R (2009) Effects of pituitary adenylate cyclase activating polypeptide and its fragments on retinal degeneration induced by neonatal monosodium glutamate treatment. Ann N Y Acad Sci 1163:348–352PubMedCrossRef

86.

Szabadfi K, Danyadi B, Kiss P, Tamas A, Fabian E, Gabriel R, Reglodi D (2012) Protective effects of vasoactive intestinal peptide (VIP) in ischemic retinal degeneration. J Mol Neurosci 48:501–507PubMedCrossRef

87.

Werling D, Banks WA, Salameh TS, Kvarik T, Kovacs LA, Vaczy A, Szabo E, Mayer F, Varga R, Tamas A, Toth G, Biro Z, Atlasz T, Reglodi D (2017) Passage through the ocular barriers and beneficial effects in retinal ischemia of topical application of PACAP1-38 in rodents. Int J Mol Sci 18(3)

88.

Werling D, Reglodi D, Banks WA, Salameh TS, Kovacs K, Kvarik T, Vaczy A, Kovacs L, Mayer F, Danyadi B, Lokos E, Tamas A, Toth G, Biro Z, Atlasz T (2016) Ocular delivery of PACAP1-27 protects the retina from ischemic damage in rodents. Invest Ophthalmol Vis Sci 57(15):6683–6691PubMedCrossRef

89.

Vaczy A, Reglodi D, Somoskeoy T, Kovacs K, Lokos E, Szabo E, Tamas A, Atlasz T (2016) The protective role of PAC1-receptor agonist maxadilan in BCCAO-induced retinal degeneration. J Mol Neurosci 60(2):186–194PubMedCrossRef

90.

Szabo A, Danyadi B, Bognar E, Szabadfi K, Fabian E, Kiss P, Mester L, Manavalan S, Atlasz T, Gabriel R, Toth G, Tamas A, Reglodi D, Kovacs K (2012) Effect of PACAP on MAP kinases, Akt and cytokine expressions in rat retinal hypoperfusion. Neurosci Lett 523:93–98PubMedCrossRef

91.

Alston EN, Parrish DC, Hasan W, Tharp K, Pahlmeyer L, Habecker BA (2011) Cardiac ischemia-reperfusion regulates sympathetic neuropeptide expression through gp130-dependent and independent mechanisms. Neuropeptides 45(1):33–42PubMedCrossRef

92.

Szanto Z, Sarszegi Z, Reglodi D, Nemeth J, Szabadfi K, Kiss P, Varga A, Banki E, Csanaky K, Gaszner B, Pinter O, Szalai Z, Tamas A (2012) PACAP immunoreactivity in human malignant tumor samples and cardiac diseases. J Mol Neurosci 48(3):667–673PubMedCrossRef

93.

Sarszegi Z, Szabo D, Gaszner B, Konyi A, Reglodi D, Nemeth J, Lelesz B, Polgar B, Jungling A, Tamas A (2018) Examination of pituitary adenylate cyclase-activating polypeptide (PACAP) as a potential biomarker in heart failure patients. J Mol Neurosci in press. https://doi.org/10.1007/s12031-017-1025-7

94.

Racz B, Gasz B, Gallyas F Jr, Kiss P, Tamas A, Szanto Z, Lubics A, Lengvari I, Toth G, Hegyi O, Roth E, Reglodi D (2008) PKA-Bad-14-3-3 and Akt-Bad-14-3-3 signaling pathways are involved in the protective effects of PACAP against ischemia/reperfusion-induced cardiomyocyte apoptosis. Regul Pept 145(1–3):105–115

95.

Roth E, Weber G, Kiss P, Horvath G, Toth G, Gasz B, Ferencz A, Gallyas F Jr, Reglodi D, Racz B (2009) Effects of PACAP and preconditioning against ischemia/reperfusion-induced cardiomyocyte apoptosis in vitro. Ann N Y Acad Sci 1163:512–516PubMedCrossRef

96.

Ji H, Zhang Y, Shen XD, Gao F, Huang CY, Abad C, Busuttil RW, Waschek JA, Kupiec-Weglinski JW (2013) Neuropeptide PACAP in mouse liver ischemia and reperfusion injury: immunomodulation by the cAMP-PKA pathway. Hepatology 57(3):1225–1237PubMedPubMedCentralCrossRef

97.

Ferencz A, Racz B, Tamas A, Reglodi D, Lubics A, Nemeth J, Nedvig K, Kalmar-Nagy K, Horvath OP, Weber G, Roth E (2009) Influence of PACAP on oxidative stress and tissue injury following small bowel autotransplantation. J Mol Neurosci 37:168–176PubMedCrossRef

98.

Ferencz A, Kiss P, Weber G, Helyes Z, Shintani N, Baba A, Reglodi D (2010) Comparison of intestinal warm ischemic injury in PACAP knock-out and wild-type mice. J Mol Neurosci 42:435–442PubMedCrossRef

99.

Laszlo E, Kiss P, Horvath G, Szakaly P, Tamas A, Reglodi D (2014) The effects of pituitary adenylate cyclase activating polypeptide in renal ischemia/reperfusion. Acta Biol Hung 65(4):369–378PubMedCrossRef

100.

Laszlo E, Varga A, Kovacs K, Jancso G, Kiss P, Tamas A, Szakaly P, Fulop B, Reglodi D (2015) Ischemia/reperfusion-induced kidney injury in heterozygous PACAP deficient mice. Transplant Proc 47:2210–2215PubMedCrossRef

101.

Szakaly P, Laszlo E, Kovacs K, Racz B, Horvath G, Ferencz A, Lubics A, Kiss P, Tamas A, Brubel R, Opper B, Baba A, Hashimoto H, Farkas J, Matkovits A, Magyarlaki T, Helyes Zs RD (2011) Mice deficient in pituitary adenylate cyclase activating polypeptide (PACAP) show increased susceptibility to in vivo renal ischemia/reperfusion injury. Neuropeptides 45:113–121PubMedCrossRef

102.

Horvath G, Racz B, Szakaly P, Kiss P, Laszlo E, Hau L, Tamas A, Helyes Zs LA, Hashimoto H, Baba A, Reglodi D (2010) Mice deficient in neuropeptide PACAP demonstrate increased sensitivity to in vitro kidney hypoxia. Transplant Proc 42:2293–2295PubMedCrossRef

103.

Horvath G, Racz B, Reglodi D, Kovacs K, Kiss P, Gallyas F Jr, Bognar Z, Szabo A, Magyarlaki T, Laszlo E, Lubics A, Tamas A, Toth G, Szakaly P (2010) Effects of PACAP on mitochondrial apoptotic pathways and cytokine expression in rats subjected to renal ischemia-reperfusion. J Mol Neurosci 42: 411–418

104.

Szakaly P, Kiss P, Lubics A, Magyarlaki T, Tamas A, Racz B, Lengvari I, Toth G, Reglodi D (2008) Effects of PACAP on survival and renal morphology in rats subjected to renal ischemia-reperfusion. J Mol Neurosci 36:89–96PubMedCrossRef

105.

Chang CL, Donaghy M, Poulter N (1999) Migraine and stroke in young women: case-control study. BMJ 318(7175):13–18PubMedPubMedCentralCrossRef

106.

Etminan M, Takkouche B, Isorna FC, Samii A (2005) Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies. BMJ 330(7482):63PubMedPubMedCentralCrossRef

107.

Schurks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T (2009) Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ 339:b3914PubMedPubMedCentralCrossRef

108.

Spector JT, Kahn SR, Jones MR, Jayakumar M, Dalal D, Nazarian S (2010) Migraine headache and ischemic stroke risk: an updated meta-analysis. Am J Med 123(7):612–624PubMedPubMedCentralCrossRef

109.

Maassen Van DenBrink A, Meijer J, Villalon CM, Ferrari MD (2016) Wiping out CGRP: potential cardiovascular risks. Trends Pharmacol Sci 37(9):779–788CrossRef

110.

Deen M, Correnti E, Kamm K, Kelderman T, Papetti L, Rubio-Beltran E, Vigneri S, Edvinsson L, Maassen Van Den Brink A (2017) Blocking CGRP in migraine patients - a review of pros and cons. J Headache Pain 18(1):96PubMedPubMedCentralCrossRef

111.

Brifault C, Vaudry D, Wurtz O (2016) The neuropeptide PACAP, a potent disease modifier candidate for brain stroke treatment. In: Pituitary adenylate cyclase activating polypeptide-PACAP, volume 11. Springer Nature, New York, pp 583–606CrossRef

Title: Protective effects of PACAP in ischemia
Authors: Dora Reglodi
Alexandra Vaczy
Eloísa Rubio-Beltran
Antoinette MaassenVanDenBrink
Publication date: 01-12-2018
Publisher: Springer Milan
Published in: The Journal of Headache and Pain / Issue 1/2018
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI: https://doi.org/10.1186/s10194-018-0845-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Protective effects of PACAP in ischemia

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2018

Comment on Castien et al. (2018) pressure pain thresholds over the cranio-cervical region in headache - a systematic review and meta-analysis

My Migraine Voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed

Sphenopalatine ganglion stimulation for cluster headache, results from a large, open-label European registry

Perampanel inhibits calcitonin gene-related peptide release from rat brainstem in vitro

Non-invasive vagus nerve stimulation for treatment of cluster headache: early UK clinical experience

Discovery of PACAP and its receptors in the brain